INTRODUCTION {#s1}
============

Among human malignant tumors, pancreatic ductal adenocarcinoma (PDAC) is the most difficult cancer to treat, and the 5-year survival rate of patients with PDAC is approximately 5% \[[@R1]\]. Owing to the lack of an effective diagnostic strategy, most patients with PDAC have local invasion or distant metastasis \[[@R2]\]. Only about 15% of patients are candidates for surgical resection, and the prognosis of patients with inoperable cancer is very poor \[[@R3]\]. Currently developed combination chemotherapies have a limited therapeutic impact on patients with advanced-stage disease \[[@R4]\]. Elucidation of the molecular mechanisms of lethal PDAC may lead to the development of novel therapeutic strategies.

MicroRNAs (miRNAs) are short noncoding RNAs that act as fine-tuners of the expression of protein-coding or noncoding genes \[[@R5]\]. In recent years, miRNAs have been shown to have both oncogenic and tumor-suppressive functions based on a variety of studies \[[@R6]\]. Currently developed bioinformatics approaches have indicated that a single miRNA can regulate many protein-coding RNAs; conversely, more than 60% of protein-coding genes in the human genome are controlled by miRNAs \[[@R7]\]. Therefore, aberrantly expressed miRNAs can disrupt entire networks of protein-coding or noncoding genes and affect the pathogenesis of human cancers.

Screening for dysregulated miRNAs in cancer cells is a critical first step to elucidating aberrantly expressed genes and proteins involved in cancer pathogenesis \[[@R8]\]. In PDAC, we have sequentially identified anti-tumor miRNAs using RNA sequencing-based miRNA expression signatures \[[@R9]--[@R11]\]. Our previous studies showed that clustered miRNAs, e.g., *miR-375*, *miR-216a-5p*, *miR-216a-3p*, *miR-216b-5p*, *miR-216b-3p*, and *miR-217*, are significantly downregulated in PDAC tissues and act as anti-tumor miRNAs \[[@R9]--[@R11]\]. Moreover, overexpression of forkhead box Q1 (*FOXQ1*) and actin-binding protein anilin (*ANLN*) promote PDAC cell aggressiveness and are involved in PDAC pathogenesis \[[@R9], [@R10]\]. These findings suggested that analysis of novel cancer pathways mediated by anti-tumor miRNAs will provide new insights into the potential mechanisms underlying the aggressive course of PDAC.

In this study, we focused on *miR-124-3p* because our functional screening showed that restoration of *miR-124-3p* markedly inhibited oncogenic signaling in PDAC cells. Here, we aimed to investigate the anti-tumor roles of *miR-124-3p* and to identify *miR-124-3p*-regulated novel oncogenic pathways in PDAC cells. The *miR-124* family includes three members, *miR-124-1*, *miR-124-2* and *miR-124-3* on different human chromosomal loci, 8q23.1, 8p12.1 and 20p13.33, respectively. The mature sequences of the three *miR-124* family are exactly the same. Since their sequences are identical, we define the *miR-124* family as *miR-124-3p* in this study. The gene structure of the *miR-124* family and the chromosomal loci are shown in the [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}.

Our present data showed that two cell-surface matrix receptors, integrin α3 (*ITGA3*) and integrin β1 (*ITGB1*), were directly regulated by *miR-124-3p* in PDAC cells. Recent studies demonstrated that dysregulation of the extracellular matrix (ECM) and integrin-mediated oncogenic signaling enhances cancer cell aggressiveness \[[@R12], [@R13]\]. Thus, *miR-124-3p*-based approaches for PDAC can be used to identify potential targets for the development of new therapeutic strategies.

RESULTS {#s2}
=======

Expression levels of *miR-124-3p* in PDAC clinical specimens and cell lines {#s2_1}
---------------------------------------------------------------------------

Expression levels of *miR-124-3p* were validated using PDAC specimens (cancer tissues: n = 30 and normal pancreatic tissues: n = 12) and three PDAC cell lines (PANC-1, SW1990, and MIApaca-2). Backgrounds and clinicopathological characteristics of clinical samples are shown in Table [1A](#T1A){ref-type="table"}. Normal pancreatic tissues are shown in Table [1B](#T1B){ref-type="table"}.

###### Characteristics of patients with PDAC

  Pancreatic ductal adenocarcinoma (PDAC)   (%)                         
  ----------------------------------------- ---------- ---------------- ----------
  Total number                                         30               
  Average age (range), years                            65.8 (42-79)    
  Sex                                       Male       15                (50.0) 
                                             Female    15               (50.0)
                                                                        
  T category                                pTis       1                (3.3)
                                            pT1        1                (3.3)
                                            pT2        1                (3.3)
                                            pT3        27               (90.1)
                                            pT4        0                \(0\)
                                                                        
  N category                                0          12               (40.0)
                                            1          18               (60.0)
                                                                        
  M category                                0          27               (90.0)
                                            1          3                (10.0)
                                                                        
  Neoadjuvant chemotherapy                  (-)        13               (43.3)
                                            (+)        17               (56.7)
                                                                        
  Recurrence                                (-)        8                (26.7)
                                            (+)        22               (73.3)

###### Characteristics of patients without PDAC

  Normal pancreatic tissue                                 
  ---------------------------- ---------- ---------------- ----------
  Total number                            12               
  Average age (range), years               65.4 (42-85)    
  Sex                          Male       5                 (41.7) 
                                Female    7                (58.3)

The expression levels of *miR-124-3p* were significantly lower in PDAC tissues than in normal pancreatic tissues (normalized to *RNU48*; *P* = 0.0029, Figure [1A](#F1){ref-type="fig"}). However, for clinicopathological factors (i.e., age, sex, neoadjuvant chemotherapy, and recurrence), there were no significant differences in the expression of *miR-124-3p*.

![Anti-tumor functions of *miR-124-3p* in PDAC cell lines and decreased phosphorylation of the components of oncogenic signaling pathways\
**(A)** Expression levels of *miR-124-3p* in PDAC clinical specimens and cell lines were determined by qRT-PCR. Data were normalized to *RNU48* expression. ^\*^, *P* \< 0.0001. **(B)** Cell proliferation was determined by XTT assays 72 h after transfection with 10 nM *miR-124-3p*. ^\*^, *P* \< 0.0001. **(C)** Cell migration activity was determined by migration assays. ^\*^, *P* \< 0.0001. **(D)** Cell invasion activity was determined using Matrigel invasion assays. ^\*^, *P* \< 0.0001. **(E)** Gain of function *miR-124-3p* in PDAC cells reduced the phosphorylation of FAK, AKT, and Erk1/2. GAPDH was used as a loading control.](oncotarget-09-28849-g001){#F1}

Expression levels of three cancer cell lines were markedly low compared to normal pancreatic tissues (Figure [1A](#F1){ref-type="fig"}).

Effects of ectopic expression of *miR-124-3p* in PDAC cells {#s2_2}
-----------------------------------------------------------

To investigate the anti-tumor roles of *miR-124-3p*, we performed gain-of-function studies using transfection of PANC-1, SW1990, and MIApaca-2 cells.

*In vitro* assays demonstrated that cell proliferation, migration, and invasion were significantly inhibited in *miR-124-3p* mimic transfectants compared those in with mock or miR-control transfectants (each, *P* \< 0.0001; Figure [1B--1D](#F1){ref-type="fig"}), with particularly remarkable effects observed in migration and invasion assays. These results indicated that *miR-124-3p* had anti-tumor roles in PDAC cells and could be categorized as an anti-tumor miRNA. We performed flow cytometric analyses to determine the number of apoptotic cells following restoration of *miR-124-3p* expression. The apoptotic cell numbers (apoptotic and early apoptotic cells) were increased in *miR-124-3p* expression than in mock or miR-control transfectant cells ([Supplementary Figure 2A and 2B](#SD1){ref-type="supplementary-material"}). We showed that cleaved PARP expression was detected in restoration of *miR-124-3p* expression ([Supplementary Figure 2C](#SD1){ref-type="supplementary-material"}).

Blocking of oncogenic signaling by ectopic expression of *miR-124-3p* in PDAC cells {#s2_3}
-----------------------------------------------------------------------------------

Next, we analyzed whether oncogenic signaling pathways were affected using gain-of-function *miR-124-3p* in PDAC cell lines. FAK, AKT, and ERK1/2 were selected as intracellular carcinogenic signaling molecules, and the phosphorylated state of each protein was evaluated by western blotting. The levels of phospho-FAK, phospho-AKT, and phospho-Erk1/2 were blocked by *miR-124-3p* expression in PDAC cells (Figure [1E](#F1){ref-type="fig"}).

Identification of *miR-124-3p*-regulated oncogenic pathways and targets in PDAC cells {#s2_4}
-------------------------------------------------------------------------------------

To identify molecular oncogenic pathways and targets regulated by *miR-124-3p* in PDAC cells, we applied a combination of *in silico* database analyses and gene expression analyses in PDAC clinical specimens. Our strategy is shown in [Supplementary Figure 3](#SD1){ref-type="supplementary-material"}.

Using the TargetScan database 7.1, we annotated 4,450 putative target genes having *miR-124-3p* binding sites in their 3′- untranslated regions (UTRs). Gene expression data (GEO accession number: GSE15471) revealed that 2,148 genes were upregulated in PDAC clinical specimens (fold-change log~2~ \> 1.0). Finally, we selected 435 genes that were putative oncogenic targets regulated by *miR-124-3p* in PDAC cells.

We categorized 435 genes into existing molecular pathways using KEGG pathway analyses. The top 10 pathways contained 60 genes (Table [2A](#T2A){ref-type="table"}). We investigated the expression statuses of those 60 genes and the clinical significance of PDAC using the OncoLnc database (<http://www.oncolnc.org/>). Kaplan-Meier survival curves showed that high expression of 15 genes was associated with poor prognosis in PDAC (Table [2B](#T2B){ref-type="table"}, Figure [2](#F2){ref-type="fig"}).

###### Enriched KEGG pathways regulated by *miR-124-3p* on in silico analysis

  KEGG ID      Pathways                                 *P* value    No. of genes   Genes
  ------------ ---------------------------------------- ------------ -------------- ------------------------------------------------------------------------------------------------------------------------------------------
  Kegg:04512   ECM-receptor interaction                 4.1783E-11   13             *SDC1, ITGA1, SDC4, ITGA3, ITGA2, HSPG2, LAMC1, COL4A1, THBS2, LAMC2, ITGB1, COL5A1, COL6A3*
  Kegg:05200   Pathways in cancer                       1.0784E-09   21             *E2F3, TGFBR1, MMP2, GLI3, ITGA3, ITGA2, ETS1, AKT3, IL8, LAMC1, COL4A1, FZD2, TGFB1, MITF, PDGFRB, LAMC2, ITGB1, RALA, PLD1, CBL, CBLB*
  Kegg:05145   Toxoplasmosis                            3.5384E-06   10             *GNAI1, TLR4, AKT3, HSPA6, LAMC1, HLA-DPB1, TGFB1, IL10RA, LAMC2, ITGB1*
  Kegg:04060   Cytokine-cytokine receptor interaction   5.5517E-06   14             *IL7R, CXCL9, TGFBR1, IL8, CCL2, TGFB1, IL10RA, PDGFRB, IFNAR2, CSF2RB, TNFRSF11B, TNFSF4, LIF, TNFSF11*
  Kegg:04510   Focal adhesion                           7.8047E-06   12             *ITGA1, ITGA3, ITGA2, AKT3, LAMC1, COL4A1, THBS2, PDGFRB, LAMC2, ITGB1, COL5A1, COL6A3*
  Kegg:04630   Jak-STAT signaling pathway               2.4297E-05   10             *IL7R, AKT3, JAK3, SPRED1, IL10RA, IFNAR2, CSF2RB, CBL, LIF, CBLB*
  Kegg:04514   Cell adhesion molecules (CAMs)           2.8873E-05   9              *CLDN1, SDC1, SDC4, MPZL1, HLA-DPB1, CLDN11, ITGB1, VCAN, CLDN4*
  Kegg:04810   Regulation of actin cytoskeleton         7.0689E-05   11             *ITGA1, ARPC5, ARPC1B, ITGA3, MYH10, ITGA2, MSN, GNA13, RRAS, PDGFRB, ITGB1*
  Kegg:04144   Endocytosis                              0.00076292   9              *SH3KBP1, TGFBR1, HSPA6, TGFB1, RAB31, DAB2, PLD1, CBL, CBLB*
  Kegg:04010   MAPK signaling pathway                   0.00596607   9              *CACNA2D1, TGFBR1, AKT3, DUSP6, HSPA6, RRAS, TGFB1, PDGFRB, MAP3K8*

###### Candidate target genes regulated by *miR-124-3p*

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Entrez gene   Gene symbol   Gene name                                                                                      Target sites   GEO data\   ^\*^TCGA_OncoLnc P-value   
                                                                                                                                            FC(log2)                               
  ------------- ------------- ---------------------------------------------------------------------------------------------- -------------- ----------- -------------------------- --------
  3675          *ITGA3*       integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)                           1              0           1.329                      0.0004

  6237          *RRAS*        related RAS viral (r-ras) oncogene homolog                                                     1              0           1.147                      0.0010

  3688          *ITGB1*       integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)   2              0           1.687                      0.0024

  3673          *ITGA2*       integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)                                   0              1           2.619                      0.0031

  5898          *RALA*        v-ral simian leukemia viral oncogene homolog A (ras related)                                   1              0           1.028                      0.0036

  6385          *SDC4*        syndecan 4                                                                                     1              0           1.030                      0.0058

  6382          *SDC1*        syndecan 1                                                                                     0              1           1.384                      0.0079

  9076          *CLDN1*       claudin 1                                                                                      0              5           1.892                      0.0092

  1364          *CLDN4*       claudin 4                                                                                      0              1           1.055                      0.0097

  4283          *CXCL9*       chemokine (C-X-C motif) ligand 9                                                               0              1           1.294                      0.0121

  1848          *DUSP6*       dual specificity phosphatase 6                                                                 1              0           1.141                      0.0137

  1293          *COL6A3*      collagen, type VI, alpha 3                                                                     0              1           2.749                      0.0154

  30011         *SH3KBP1*     SH3-domain kinase binding protein 1                                                            1              0           1.652                      0.0264

  2535          *FZD2*        frizzled family receptor 2                                                                     0              1           1.295                      0.0349

  4478          *MSN*         moesin                                                                                         0              2           1.740                      0.0389

  7058          *THBS2*       thrombospondin 2                                                                               1              1           3.986                      0.0572

  7046          *TGFBR1*      transforming growth factor, beta receptor 1                                                    1              0           1.567                      0.0587

  3918          *LAMC2*       laminin, gamma 2                                                                               0              1           2.761                      0.0595

  2113          *ETS1*        v-ets avian erythroblastosis virus E26 oncogene homolog 1                                      1              1           1.156                      0.0674

  161742        *SPRED1*      sprouty-related, EVH1 domain containing 1                                                      1              0           1.539                      0.1010

  3587          *IL10RA*      interleukin 10 receptor, alpha                                                                 0              2           1.268                      0.1380

  3718          *JAK3*        Janus kinase 3                                                                                 0              1           1.005                      0.1670

  11031         *RAB31*       RAB31, member RAS oncogene family                                                              0              1           2.855                      0.1680

  4286          *MITF*        microphthalmia-associated transcription factor                                                 2              0           1.117                      0.2120

  3976          *LIF*         leukemia inhibitory factor                                                                     1              2           1.161                      0.2140

  4628          *MYH10*       myosin, heavy chain 10, non-muscle                                                             1              0           1.142                      0.2170

  868           *CBLB*        Cbl proto-oncogene B, E3 ubiquitin protein ligase                                              0              1           1.434                      0.2380

  8600          *TNFSF11*     tumor necrosis factor (ligand) superfamily, member 11                                          1              0           1.412                      0.2850

  6347          *CCL2*        chemokine (C-C motif) ligand 2                                                                 0              1           1.086                      0.2990

  10000         *AKT3*        v-akt murine thymoma viral oncogene homolog 3                                                  2              0           1.023                      0.3170

  3339          *HSPG2*       heparan sulfate proteoglycan 2                                                                 0              1           1.080                      0.3290

  1289          *COL5A1*      collagen, type V, alpha 1                                                                      0              1           3.496                      0.3300

  10672         *GNA13*       guanine nucleotide binding protein (G protein), alpha 13                                       2              0           1.109                      0.3300

  781           *CACNA2D1*    calcium channel, voltage-dependent, alpha 2/delta subunit 1                                    1              0           1.619                      0.3690

  1439          *CSF2RB*      colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)              0              1           1.386                      0.3940

  1462          *VCAN*        versican                                                                                       1              1           4.155                      0.4380

  4313          *MMP2*        matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)          0              2           2.531                      0.4450

  3575          *IL7R*        interleukin 7 receptor                                                                         0              1           1.444                      0.4530

  3115          *HLA-DPB1*    major histocompatibility complex, class II, DP beta 1                                          0              1           1.232                      0.4540

  7099          *TLR4*        toll-like receptor 4                                                                           0              3           1.095                      0.5340

  867           *CBL*         Cbl proto-oncogene, E3 ubiquitin protein ligase                                                3              2           1.058                      0.5750

  1282          *COL4A1*      collagen, type IV, alpha 1                                                                     1              1           2.357                      0.5830

  4982          *TNFRSF11B*   tumor necrosis factor receptor superfamily, member 11b                                         0              1           1.697                      0.6000

  3455          *IFNAR2*      interferon (alpha, beta and omega) receptor 2                                                  0              1           1.072                      0.6180

  3672          *ITGA1*       integrin, alpha 1                                                                              0              2           1.561                      0.6330

  2770          *GNAI1*       guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1        1              0           1.210                      0.6980

  10095         *ARPC1B*      actin related protein 2/3 complex, subunit 1B, 41kDa                                           1              0           1.572                      0.7020

  5010          *CLDN11*      claudin 11                                                                                     0              1           2.540                      0.7350

  3915          *LAMC1*       laminin, gamma 1 (formerly LAMB2)                                                              3              1           1.347                      0.7430

  5337          *PLD1*        phospholipase D1, phosphatidylcholine-specific                                                 1              0           1.395                      0.7630

  5159          *PDGFRB*      platelet-derived growth factor receptor, beta polypeptide                                      0              1           1.799                      0.7750

  7292          *TNFSF4*      tumor necrosis factor (ligand) superfamily, member 4                                           0              1           1.575                      0.7930

  1601          *DAB2*        Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila)                                 1              0           1.036                      0.8810

  7040          *TGFB1*       transforming growth factor, beta 1                                                             0              1           1.423                      0.8930

  9019          *MPZL1*       myelin protein zero-like 1                                                                     1              0           1.002                      0.8940

  3576          *IL8*         interleukin 8                                                                                  0              1           3.240                      0.9220

  1326          *MAP3K8*      mitogen-activated protein kinase kinase kinase 8                                               0              1           1.352                      0.9280

  10092         *ARPC5*       actin related protein 2/3 complex, subunit 5, 16kDa                                            0              1           1.038                      0.9440

  3310          *HSPA6*       heat shock 70kDa protein 6 (HSP70B\')                                                          0              1           1.347                      0.9560

  2737          *GLI3*        GLI family zinc finger 3                                                                       1              0           1.343                      0.9890
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^\*^Kaplan-Meier analysis Log-rank.

P-value \< 0.05 Poor prognosis with a high expression.

![Kaplan-Meier analysis of *miR-124-3p*-regulated genes related to poor prognosis in PDAC\
Kaplan--Meier plots of overall survival with log-rank tests between those with high and low *miR-124-3p* expression and expression of 15 genes in the PDAC TCGA database.](oncotarget-09-28849-g002){#F2}

Furthermore, we provided a heatmap gene visualization and validated as a prognostic ability of these 15 genes (Figure [3](#F3){ref-type="fig"}). As shown in Figure [3](#F3){ref-type="fig"}, patients with high gene signature expressions (Z-score \> 0) were significantly poor Overall Survival (OS) and Disease Free Survival (DFS) rate than those with low gene signature expressions (Z-score ≤ 0) (OS; *P* = 0.0011, DFS; *P* = 0.0132, Figure [3](#F3){ref-type="fig"}). Combination analysis of *ITGA3* and *ITGB1* revealed that high expression of *ITGA3/ITGB1* (Z-score \> 0) was predicted significantly poor OS and DFS rate than those with low expression of *ITGA3/ITGB1* (Z-score ≤ 0) (OS; *P* = 0.0037, DFS; *P* = 0.0162, [Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). In this study, we focused on *ITGA3* and *ITGB1*.

![Combination analysis with heatmap of 15 target genes related to poor prognosis in PDAC\
Heatmap was created using analysis webcite "R2: Genomics Analysis and Visualization Platform (<http://r2.amc.nl>)". Z - score was evaluated by a combination of *miR-124-3p* final target genes based on TCGA datasets. High group (mRNA Z-score \> 0) and low group (mRNA Z-score ≤ 0) are displayed as Kaplan--Meier plots with log-rank tests.](oncotarget-09-28849-g003){#F3}

Overexpression of *ITGA3* and *ITGB1* in PDAC tissues and cell lines {#s2_5}
--------------------------------------------------------------------

We evaluated the expression levels of *ITGA3* and *ITGB1* in PDAC tissues (n = 30), normal pancreatic tissues (n = 12), and three PDAC cell lines (PANC-1, SW1990, and MIApaca-2). The expression levels of *ITGA3 and ITGB1* were significantly upregulated in PDAC tissues compared with normal pancreatic tissues (normalized to *GUSB*: *P* = 0.0004, Figure [4A](#F4){ref-type="fig"} and P = 0.0006, Figure [5A](#F5){ref-type="fig"}).

![Direct regulation of *ITGA3* by *miR-124-3p* in PDAC cell lines\
**(A)** Expression levels of *ITGA3* in PDAC clinical specimens and cell lines were determined by qRT-PCR. Data were normalized to *GUSB* expression. **(B)** Expression levels of *ITGA3* and *miR-124-3p* were negatively correlated. **(C)** *ITGA3* mRNA expression in PDAC cell lines was evaluated by qRT-PCR 72 h after transfection with *miR-124-3p*. *GUSB* was used as an internal control. ^\*^, *P* \< 0.0001. **(D)** ITGA3 protein expression in PDAC cell lines was evaluated by western blot analysis 96 h after transfection with *miR-124-3p*. GAPDH was used as a loading control. **(E)** *miR-124-3p* binding sites in the 3′-UTR of *ITGA3* mRNA. Dual luciferase reporter assays using vectors encoding the putative *miR-124-3p* (positions 1160-1166) target site of the *ITGA3* 3′-UTR for both wild-type and deleted regions. Normalized data were calculated as ratios of *Renilla*/firefly luciferase activities. ^\*^, *P* \< 0.0001.](oncotarget-09-28849-g004){#F4}

![Direct regulation of *ITGB1* by *miR-124-3p* in PDAC cell lines\
**(A)** Expression levels of *ITGB1* in PDAC clinical specimens and cell lines were determined by qRT-PCR. Data were normalized to *GUSB* expression. **(B)** Expression levels of *ITGB1* and *miR-124-3p* were negatively correlated. **(C)** *ITGB1* mRNA expression in PDAC cell lines was evaluated by qRT-PCR 72 h after transfection with *miR-124-3p*. *GUSB* was used as an internal control. ^\*^, *P* \< 0.0001. **(D)** ITGB1 protein expression in PDAC cell lines was evaluated by western blot analysis 96 h after transfection with *miR-124-3p*. GAPDH was used as a loading control. **(E)** *miR-124-3p* binding sites in the 3′-UTR of *ITGB1* mRNA. Dual luciferase reporter assays using vectors encoding the putative *miR-124-3p* (positions 236--242 and 1095-1101) target sites of the *ITGB1* 3′-UTR for both wild-type and deleted regions. Normalized data were calculated as ratios of *Renilla*/firefly luciferase activities. ^\*^, *P* \< 0.0001.](oncotarget-09-28849-g005){#F5}

Negative correlations between *miR-124-3p* expression and *ITGA3* mRNA expression were analyzed by Spearman\'s rank test (*R* = −0.496, *P* \< 0.0013, Figure [4B](#F4){ref-type="fig"}). Additionally, negative correlations between *miR-124-3p* expression and *ITGB1* mRNA expression were analyzed by Spearman\'s rank test (R = −0.543, *P* = 0.0004, Figure [5B](#F5){ref-type="fig"}).

Direct regulation of *ITGA3* and *ITGB1* by *miR-124-3p* in PDAC cells {#s2_6}
----------------------------------------------------------------------

We performed qRT-PCR to validate *miR-124-3p* repression of *ITGA3* mRNA expression in PDAC cell lines. Our studies revealed that *ITGA3* mRNA was significantly reduced in *miR-124-3p* mimic transfectants in comparison with mock or miR-control transfectants (*P* \< 0.0001, Figure [4C](#F4){ref-type="fig"}). Expression of ITGA3 protein was also repressed in the *miR-124-3p* mimic transfectants (Figure [4D](#F4){ref-type="fig"}). *In silico* analysis using TargetScan database 7.1 showed that the 3′-UTR of *ITGA3* harbored one binding site for *miR-124-3p* (Figure [4E](#F4){ref-type="fig"}). To determine whether *ITGA3* mRNAs had functional target site, we performed dual luciferase reporter assays. Compared with the miR-control, luminescence intensity was significantly reduced by transfection with *miR-124-3p* at *miR-124-3p* target sites, position 1160-1166 in the 3′-UTR of *ITGA3* (Figure [4E](#F4){ref-type="fig"}).

Similarly, we performed qRT-PCR to validate *miR-124-3p* repression of *ITGB1* mRNA expression in PDAC cell lines. Our studies revealed that *ITGB1* mRNA was significantly reduced in *miR-124-3p* mimic transfectants in comparison with mock or miR-control transfectants (*P* \< 0.0001, Figure [5C](#F5){ref-type="fig"}). Expression of ITGB1 protein was also repressed in the *miR-124-3p* mimic transfectants (Figure [5D](#F5){ref-type="fig"}). *In silico* analysis using TargetScan database 7.1 showed that the 3′-UTR of *ITGB1* harbored two binding sites for *miR-124-3p* (Figure [5E](#F5){ref-type="fig"}). To determine whether *ITGB1* mRNAs had functional target sites, we performed dual luciferase reporter assays. Compared with the miR-control, luminescence intensity was significantly reduced by transfection with *miR-124-3p* at *miR-124-3p* target sites, both position-1 236-242 in the 3′-UTR of *ITGB1* (Figure [5E](#F5){ref-type="fig"}, upper) and position-2 1095-1101 in the 3′-UTR of *ITGB1* (Figure [5E](#F5){ref-type="fig"}, lower)

Effects of *ITGA3* and *ITGB1* knockdown in PDAC cells {#s2_7}
------------------------------------------------------

To validate the oncogenic functions of *ITGA3* and *ITGB1* in PDAC cells, we performed knockdown assays using siRNAs (si-*ITGA3* and si-*ITGB1*).

First, we evaluated the knockdown efficiency of si-*ITGA3* and si-*ITGB1* transfection in PDAC cell lines. In this study, we used two types of si-*ITGA3* (si-*ITGA3*-1 and si-*ITGA3*-2) and si-*ITGB1* (si-*ITGB1*-1 and si-*ITGB1*-2). Our data showed that all siRNAs effectively reduced *ITGA3* and *ITGB1* mRNA levels of expression in PDAC cell lines (Figures [6A](#F6){ref-type="fig"} and [7A](#F7){ref-type="fig"}). Furthermore, all siRNAs effectively reduced ITGA3 and ITGB1 protein levels of expression in PDAC cell lines (Figures [6B](#F6){ref-type="fig"} and [7B](#F7){ref-type="fig"}).

![*ITGA3* mRNA and protein expression after si-*ITGA3* transfection and effects of *ITGA3* silencing in PDAC cell lines\
**(A)** *ITGA3* mRNA expression in PDAC cell lines was evaluated by qRT-PCR 72 h after transfection with si-*ITGA3*-1 or si-*ITGA3*-2. *GUSB* was used as an internal control. **(B)** ITGA3 protein expression in PDAC cell lines was evaluated by western blot analysis 96 h after transfection with si-*ITGA3-1* and si-*ITGA3-2*. GAPDH was used as a loading control. **(C)** Cell proliferation was determined using XTT assays 72 h after transfection with 10 nM si-*ITGA3*-1 or si-*ITGA3*-2. ^\*^, *P* \< 0.0001. **(D)** Cell migration activity was determined using migration assays. ^\*^, *P* \< 0.0001. **(E)** Cell invasion activity was determined by Matrigel invasion assays. ^\*^, *P* \< 0.0001.](oncotarget-09-28849-g006){#F6}

![*ITGB1* mRNA and protein expression after si-*ITGB1* transfection and effects of *ITGB1* silencing in PDAC cell lines\
**(A)** *ITGB1* mRNA expression in PDAC cell lines was evaluated by qRT-PCR 72 h after transfection with si-*ITGB1*-1 or si-*ITGB1*-2. *GUSB* was used as an internal control. **(B)** ITGB1 protein expression in PDAC cell lines was evaluated by western blot analysis 96 h after transfection with si-*ITGB1-1* and si-*ITGB1-2*. GAPDH was used as a loading control. **(C)** Cell proliferation was determined with the XTT assays 72 h after transfection with 10 nM si-*ITGB1*-1 or si-*ITGB1*-2. ^\*^, *P* \< 0.0001. **(D)** Cell migration activity was determined using migration assays. ^\*^, *P* \< 0.0001. **(E)** Cell invasion activity was determined by Matrigel invasion assays. ^\*^, *P* \< 0.0001.](oncotarget-09-28849-g007){#F7}

Moreover, cancer cell proliferation, migration, and invasion abilities were suppressed by knockdown of these genes (Figures [6C-6E](#F6){ref-type="fig"} and [7C-7E](#F7){ref-type="fig"}). The apoptotic cell numbers were increased in si-*ITGA3* or si-*ITGB1* transfectant cells than in mock or siRNA-control transfectant cells ([Supplementary Figure 2A and 2B](#SD1){ref-type="supplementary-material"}). We showed that cleaved PARP expression was detected in transfectant cells into si-*ITGA3* or si-*ITGB1* ([Supplementary Figure 2C](#SD1){ref-type="supplementary-material"}).

Expression of ITGA3 and ITGB1 in PDAC clinical specimens and its clinical significance {#s2_8}
--------------------------------------------------------------------------------------

Next, we confirmed the expression of ITGA3 and ITGB1 proteins in PDAC clinical specimens using immunohistochemistry (IHC). In total, 30 PDAC specimens were evaluated. ITGA3 showed intracellular and membrane immunoreactivity in PDAC tissue, whereas ITGB1 showed medium membrane immunoreactivity in PDAC tissue (Figure [8A](#F8){ref-type="fig"}). For ITGA3-IHC staining, we categorized into "Weak" and "Strong" depending on the intensity of staining. (Figure [8B](#F8){ref-type="fig"}), OS and DFS were evaluated by Kaplan-Meier analysis, OS was shown that strong staining has poor prognosis with significant (*P* = 0.0336, Figure [8C](#F8){ref-type="fig"}). Details of clinicopathologic factors was shown in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. High ITGA3 expression was significantly associated with increased lymph node metastasis. In contrast, there were no significant relationships between ITGB1-IHC staining.

![Expression levels of ITGA3/ITGB1 as determined by immunohistochemical staining in PDAC specimens\
Immunohistochemical staining of ITGA3/ITGB1 in PDAC specimens. **(A)** All differentiated types of PDAC (well, moderately, poorly) showed immunoreactivity (left panel: hematoxylin-eosin staining, middle panel: ITGA3 staining, right panel: ITGB1 staining, original magnification, 200×). **(B)** Immunostaining of ITGA3 was classified by Weak (left panel) and Strong (right panel). The expression of ITGA3 was evaluated using high-power microscopy (400×). **(C)** Kaplan-Meier curves for OS and DFS rates based on ITGA3 expression in 30 patients with PDAC. P-values were calculated using the log-rank test.](oncotarget-09-28849-g008){#F8}

Finally, we examined the relationships between integrin expression and clinicopathological factors using TCGA database. There were no significant differences in terms of T, N, M, and TNM stages. However, high expression of *ITGA3* was significantly associated with recurrence. In addition, DFS was significantly shorter in the high expression group ([Supplementary Figure 5](#SD1){ref-type="supplementary-material"}). In contrast, there were no significant relationships between *ITGB1* expression and clinicopathological factors.

DISCUSSION {#s3}
==========

PDAC is the most lethal type of gastrointestinal cancer because it often does not cause any signs or symptoms in the early stages \[[@R1]\]. Moreover, there are no effective treatment strategies for patients with advanced stage PDAC, and the prognosis is extremely poor. Elucidation of the aggressive nature of PDAC based on current genomic approaches will provide important insights into novel treatment strategies for this disease. We have sequentially identified novel oncogenic RNA networks based on PDAC miRNA analyses \[[@R10]\]. Our recent studies showed that the *miR-216* family and *miR-217* were downregulated in PDAC tissues and that these miRNAs acted as anti-tumor miRNAs by targeting *FOXQ1* and *ANLN*, respectively \[[@R9], [@R10]\]. Additionally, overexpression of *FOXQ1* and *ANLN* has been shown to promote cancer cell aggressiveness and is involved in PDAC pathogenesis \[[@R9], [@R10]\].

In this study, we focused on *miR-124-3p* because miRNA functional assays showed that ectopic expression of *miR-124-3p* dramatically inhibited cancer cell migration and invasion by blocking several oncogenic signals. Previous studies have indicated that *miR-124-3p* is a bona fide anti-tumor miRNA in several cancers, e.g., glioblastoma, esophageal cancer, hepatocellular carcinoma \[[@R14]--[@R16]\]. These studies showed that overexpression of *miR-124-3p* inhibited cancer cells migration and invasion abilities through targeting several oncogenes, e.g., *IQGAP1*, *LAMC1*, *ITGB1*, *STAT3*, *SP1* \[[@R14]--[@R16]\]. Other studies indicated that promoter region of *miR-124* genes (*miR-124-1*, *miR-124-2* and *miR-124-3*) were methylated in cancer cells \[[@R17], [@R18]\]. In PDAC cells, all member of *miR-124* family were highly methylated in PDAC tissues compared with in non-cancerous tissues by pyrosequencing analysis \[[@R19]\]. Epigenetic modification of *miR-124* genes is greatly involved in silencing *miR-124-3p* expression in several cancer cells. Our data confirmed that *miR-124-3p* acted as an anti-tumor miRNA in PDAC cells, consistent with previous reports \[[@R19]\].

Next, we aimed to discover molecular networks controlled by anti-tumor *miR-124a-3p* in PDAC cells. To identify *miR-124-3p*-regulated networks, we applied *in silico* database analyses depending on a strategy we created independently \[[@R9]--[@R11]\]. Several pathways were found to be regulated by *miR-124-3p* in PDAC cells, including ECM-receptor interactions, pathways in cancer, cytokine-cytokine receptor interactions, focal adhesion, and actin cytoskeleton regulation. Finally, a total of 60 genes were identified as putative targets of *miR-124-3p* in PDAC cells. We further analyzed the genes involved in these pathways and PDAC pathogenesis using TCGA database. Importantly, among 60 putative targets, high expression of 15 genes (*ITGA3*, *RRAS*, *ITGB1*, *ITGA2*, *RALA*, *SDC4*, *SDC1*, *CLDN1*, *CLDN4*, *CXCL9*, *DUSP6*, *COL6A3*, *SH3KBP1*, *FZD2*, and *MSN*) was significantly associated with poor prognosis in patients with PDAC. Interestingly, many of these genes were involved in ECM/integrin signaling. The ECM is an assembly of extracellular molecules secreted by cells and provides structural and biochemical support to surrounding cells \[[@R20], [@R21]\]. Many studies have indicated that aberrant expression of ECM-related genes and activation of integrin-mediated signaling enhance cancer cell migration and invasion abilities in several cancers \[[@R22], [@R23]\]. Moreover, dysregulation of these genes is involved in the pathogenesis of PDAC \[[@R24]\], and detailed analyses of the functional significance of these genes in PDAC cells are necessary.

Integrins are a family of transmembrane cell adhesion receptors that are responsible for mutual cell-to-cell or cell-to-ECM, e.g., laminin, collagen, elastin, and fibronectin, communication \[[@R25]\]. Integrin receptors composed of specific two subunits (α and β) and up to 24 distinct integrin receptors have been reported \[[@R26]\]. Overexpression of integrins and activation of integrin-mediated oncogenic signaling have been reported in several cancers, affecting neighboring cancer cells or surrounding stromal cells and enhancing cancer cell aggressiveness and metastasis \[[@R27], [@R28]\]. Our recent studies have shown that anti-tumor miRNAs, e.g., the *miR-29* family, *miR-150*s, the *miR-199* family, *miR-218*, and *miR-223*, directly regulate several integrins, and these ligands and ectopic expression of these miRNAs have dramatically prevented cancer cell malignancy. \[[@R12], [@R13], [@R29]--[@R31]\]

Our present data showed that both *ITGA3* and *ITGB1* were directly regulated by anti-tumor *miR-124-3p* in PDAC cells, and knockdown of these genes or ectopic expression of *miR-124-3p* significantly blocked cancer cell aggressiveness. Moreover, overexpression of *ITGA3* and *ITGB1* was involved in PDAC pathogenesis. *ITGA3* and *ITGB1* form a specific type of integrin receptor (*ITGA3*/*ITGB1*), and dysregulation of *ITGA3*/*ITGB1*-mediated signaling enhances cancer cell aggressiveness in several types of cancer \[[@R32]--[@R34]\]. *ITGB1* can form 18 receptor heterodimers with various partners (integrin α-subunits), and these receptors regulate numerous signaling pathways under both physiological and pathophysiological conditions \[[@R35]\]. Overexpression of *ITGB1* has been frequently observed in several cancers, including PDAC \[[@R36]\]. Therefore, blocking *ITGB1*, e.g., using small molecules or antibodies, may be an effective approach for the treatment of lethal PDAC \[[@R37]\]. Furthermore, our findings revealed that *ITGA3* affected PDAC prognosis by altering recurrence and DFS. Anti-tumor *miR-124-3p* regulates important intracellular pathways for pancreatic cancer via dual *ITGA3*/*ITGB1*. Identification of novel anti-tumor miRNA-mediated RNA networks may contribute to the development of new therapeutic strategies. *ITGA2* is also reported as a partner subunit of *ITGB1* \[[@R38]\]. Our analysis showed that *ITGA2* was identified as *miR-124-3p* target and its expression was associated with poor prognosis of the patients with PDAC ([Supplementary Figure 6](#SD1){ref-type="supplementary-material"}). Previous studies showed that blocking of *ITGA2* inhibited cancer cell aggressiveness \[[@R39]\]. Therefore, it is necessary to analyze the functional significance of *ITGA2* in PDAC pathogenesis.

In conclusion, the anti-tumor roles of *miR-124-3p* were achieved in PDAC cells through inhibition of several oncogenic signaling pathways. Oncogenic pathways and targets regulated by *miR-124-3p* were involved in PDAC molecular pathogenesis. This is the first report demonstrating that the pivotal oncogenic receptors *ITGA3* and *ITGB1* were directly controlled by *miR-124-3p* in PDAC cells. Overexpression of these receptors was significantly associated with poor prognosis in patients with PDAC. Novel approaches based on anti-tumor miRNA-mediated oncogenic pathways and targets may contribute to the development of effective therapies for PDAC.

MATERIALS AND METHODS {#s4}
=====================

Clinical pancreatic specimens and PDAC cell lines {#s4_1}
-------------------------------------------------

In total, 30 PDAC specimens were obtained from patients who had undergone curative surgical resection at Kagoshima University Hospital from 1997 to 2016. Twelve normal pancreatic tissue specimens were collected from noncancerous regions. Frozen specimens were used for gene expression analysis, and paraffin sections were used for immunohistochemistry. The samples were staged according to the American Joint Committee on Cancer--Union Internationale Contre le Cancer (UICC) TNM classification \[[@R40]\].

The present study was approved by the Institutional Review Board of Kagoshima University; prior written informed consent and approval was given by each patient.

Three human PDAC cell lines (PANC-1, SW1990, and MIApaca-2) obtained from RIKEN Cell Bank (Tsukuba, Ibaraki, Japan) and the American Type Culture Collection (Manassas, VA, USA) were used for this study.

RNA containing miRNAs was extracted using ISOGEN (NIPPON GENE, Toyama, Japan), according to the manufacturer\'s instructions.

Quantitative real-time polymerase chain reaction (qRT-PCR) {#s4_2}
----------------------------------------------------------

TaqMan qRT-PCR probes and primers were obtained from Thermo Fisher Scientific (Waltham, MA, USA) as follows: *miR-124-3p* (product ID: 000446; Thermo), *ITGA3* (product ID: Hs01076879_m1), *ITGB1* (product ID: Hs01127536_m1) and *ITGA2* (product ID: Hs00158127_m1). *GUSB* (product ID: Hs99999908_m1) and *RNU48* (product ID: 001006) were used as internal controls. The procedure for qRT-PCR was described in previous studies \[[@R30], [@R41]\].

Transient transfection of mature miRNAs and small interfering RNAs (siRNAs) into cancer cells {#s4_3}
---------------------------------------------------------------------------------------------

Pre-miR miRNA precursors and siRNAs were purchased from Thermo Fisher Scientific, as follows: *miR-124-3p* (product ID: PM 10245), negative control miRNA (product ID: AM 17111), two *ITGA3* siRNAs (product IDs: HSS105529 and HSS179967), two *ITGB1* siRNAs (product IDs: HSS105559 and HSS105561), and negative control siRNA (product ID: D-001810-10). Lipofectamine RNAiMAX and Lipofectamine 2000 (Thermo Fisher Scientific) were used for transfection into PDAC cell lines. The transfection efficiencies of miRNA in cancer cells were calculated as described in previous studies \[[@R42]\].

Cell proliferation, migration, and invasion assays {#s4_4}
--------------------------------------------------

Cell proliferation was evaluated using a Cell Proliferation Kit II (Roche Applied Sciences, Penzberg, Germany). Cell migration was evaluated using BD Falcon Cell Culture Inserts (BD Biosciences, Franklin Lakes, NJ, USA), and cell invasion was evaluated using Corning BioCoat Matrigel Invasion Chambers (Corning, NY, USA). The protocols for functional assays were described previously \[[@R11], [@R13], [@R30]\].

Identification of *miR-124-3p* targets in PDAC cells {#s4_5}
----------------------------------------------------

To identify *miR-124-3p* target genes, we performed a combination of genome-wide gene expression analyses and *in silico* database analyses as described in previous studies \[[@R9]--[@R11], [@R43]\].

We selected putative miRNA target genes using the Target Scan Human 7.1 database (<http://www.targetscan.org/vert_71>), GEO microarray database (<https://www.ncbi.nlm.nih.gov/geo/>/; accession number GSE15471), to analyze gene expression levels in 36 PDAC samples versus 36 normal pancreatic tissue samples. Finally, The Cancer Genome Atlas (TCGA) database (<https://cancergenome.nih.gov/>) was used for analysis of gene expression in PDAC. The strategy for selecting target genes in this study is shown in [Supplementary Figure 3](#SD1){ref-type="supplementary-material"}.

TCGA database analysis of PDAC samples {#s4_6}
--------------------------------------

To investigate the clinical significance of the expression status of putative targets of *miR-124-3p* in patients with PDAC, we analyzed TCGA datasets (<https://gdc.nci.nih.gov/>). A large amount of cohort data was retrieved from cBioPortal (<http://www.cbioportal.org/>) and OncoLnc (data downloaded on November 1, 2017). Detailed information on the method is described in a previous paper \[[@R44]--[@R45]\]. The Z-scores of target genes mRNA expression data and clinical sample information corresponding to PDAC patients were collected from cBioPortal. R2: Genomics Analysis and Visualization Platform (<http://r2.amc.nl>) was used to create a heatmap. Furthermore, Z- score was evaluated by a combination of each genes sets. High group (mRNA Z-score \> 0) and low group (mRNA Z-score ≤ 0) were analyzed by Kaplan--Meier survival curves and log-rank statistics.

Plasmid construction and dual-luciferase reporter assay {#s4_7}
-------------------------------------------------------

Wild-type or deletion-type sequences of the 3′-UTR of *ITGA3* and *ITGB1* in *miR-124-3p* target sites were inserted into the psiCHECK-2 vector (C8021; Promega, Madison, WI, USA). The procedure for dual luciferase reporter assays was described previously \[[@R11], [@R12], [@R42]\].

Western blot analyses {#s4_8}
---------------------

Antibodies used in the phosphorylation pathway were purchased from Cell Signaling Technology (Danvers, MA, USA) as follows: anti-focal adhesion kinase (FAK) antibodies (product ID: \#3285), anti-phospho-FAK antibodies (product ID: \#8556), anti-AKT antibodies (product ID: \#4691), anti-phospho-AKT antibodies (product ID: \#4060), anti-extracellular signal-regulated kinase (Erk) 1/2 antibodies (product ID: \#4695), and anti-phospho-Erk1/2 antibodies (product ID: \#4370).

To investigate the expression of *miR-124-3p* targets, anti-ITGA3 antibodies (HPA008572; Sigma-Aldrich, St. Louis, MO, USA) and anti-ITGB1 antibodies (\#9699; Cell Signaling Technology) were used for western blotting, PARP antibody (product ID: 9542; Cell Signaling Technology, Danvers, USA) was used for apoptosis assay, usage was according to each data sheet. Anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies (product ID: SAF6698; Wako, Osaka, Japan) were used as an internal loading control for western blotting. A detailed description of the western blotting procedure was published elsewhere \[[@R11]\].

Immunohistochemistry {#s4_9}
--------------------

Tissue sections were incubated overnight at 4°C with anti-ITGA3 antibodies diluted 1:200 (HPA008572; Sigma-Aldrich, St. Louis, MO, USA) and anti-ITGB1 antibodies diluted 1:100 (\#9699; Cell Signaling Technology). The IHC score was calculated by judging the percentage of positively stained plasma membrane in cancer cells. The scores ranged from 1 to 3 (1; \<5%, 2; 5--50%, and 3; \>50% immunoreactive cells). Scores 1 and 2 were considered to indicate "weak" expression, while scores 3 indicated "Strong" expression of ITGA3.

Statistical analysis {#s4_10}
--------------------

Mann-Whitney U-tests were used for analysis between two groups, and Bonferroni-adjusted Mann-Whitney U-tests were used for analysis among multiple groups. Correlations between the expression of *miR-124-3p* and *ITGA3/ITGB1* were evaluated using Spearman\'s rank tests. Overall survival (OS) and disease-free survival (DFS) after surgery were analyzed using Kaplan--Meier curves and evaluated with log-rank tests. We used Expert StatView software (version 5.0 SAS Institute Inc., Cary, NC, USA) for these analyses.

SUPPLEMENTARY MATERIALS FIGURES AND TABLE {#s5}
=========================================
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